Oaktree Acquisition Corp. III Life Sciences
OACCU- Exchange
- Nasdaq
- Industry
- Blank Checks
- SEC CIK
- 0002029769
No open-market purchases or sales by Oaktree Acquisition Corp. III Life Sciences insiders were filed in the last 90 days; 5 institutions reported holding it in 13F filings for Q2 2026, worth $9.24M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −1 vs. previous quarter
- 5
- 13F valueReported value at the end of Q2 2026
- $9.24M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding OACCU, Q2 2026
No superinvestor reported holding OACCU at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Oaktree Acquisition Corp. III Life Sciences insiders from Form 4, newest first.
No open-market purchases or sales by Oaktree Acquisition Corp. III Life Sciences insiders are on file.
Top 10 13F holders, Q2 2026
The largest institutional positions in Oaktree Acquisition Corp. III Life Sciences at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 516,482 | $5.60M | 0.26% | 00.0% | Unchanged |
| Affinity Asset Advisors, LLC | 250,000 | $2.75M | 0.13% | 00.0% | Unchanged |
| Athos Capital Ltd | 50,000 | $550.0K | 0.20% | 00.0% | Unchanged |
| Clear Street Group Inc. | 21,975 | $241.7K | 0.00% | −246−1.1% | Reduced |
| UBS Group AG | 9,464 | $104.1K | 0.00% | −301−3.1% | Reduced |